Results 11 to 20 of about 235 (94)
Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations. [PDF]
Anal Cell Pathol (Amst), 2021 Chronic myeloid leukemia (CML) is a disease of hematopoietic stem cells and is caused by the balanced translocations among the long arms of chromosomes 9 and 22, which are called the Philadelphia (Ph) chromosome. In this study, 131 CML patients were enrolled.
Asif M +8 more
europepmc +2 more sources
EHA2021 Virtual Congress Abstract Book
, 2021 HemaSphere, Volume 5, Issue S2, June 2021.
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 150, June 2019., 2019 Background: BCR‐ABL‐targeted tyrosine kinase inhibitors (TKI) revolutionized the outcome of patients inflicted with CML and Ph+ B‐ALL. However, TKI resistance continues to pose challenges for both CML and ALL. Aims: We hypothesized that overcoming the BM microenvironment‐mediated protection of Ph+ leukemic cells from TKI‐mediated apoptosis may further ...
K. Beider +9 more
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 151, June 2019., 2019 Background: Approximately 50% of chronic myeloid leukemia (CML) patients in deep remission experience a return of clinical CML after withdrawal of tyrosine kinase inhibitors (TKIs), suggesting signaling of catalytically inactive BCR‐ABL. This allows for survival of cancer cells responsible for CML relapse after discontinuation of the TKI therapy ...
T. Gregor +6 more
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 151, June 2019., 2019 Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by a fusion protein, the constitutively active BCR–ABL tyrosine kinase, leading to expansion of differentiated granulocytes. Although tyrosine kinase inhibitors (TKI) have significantly improved patient care, minimal residual disease (MRD) remains a clinical ...
A.B. Herrmann +8 more
wiley +1 more source
PF399 GENE EXPRESSION PROFILING OF CD26+ LEUKEMIC STEM CELL POPULATION FROM CML PATIENTS
HemaSphere, Volume 3, Issue S1, Page 151-152, June 2019., 2019 Background: Nowadays, chronic myeloid leukemia (CML) has become a well manageable disease and majority of the patients achieve remission on tyrosine kinase inhibitor (TKI) treatment. However, the disease usually shows a low‐level persistence during therapy that arises from putative leukemic stem cells (LSC), which are, despite BCR‐ABL1 positivity ...
D. Smitalová +6 more
wiley +1 more source
PF401 IMMUNE SYSTEM AND CHRONIC MYELOID LEUKEMIA: THE IMPACT OF TYROSINE KINASE INHIBITORS
HemaSphere, Volume 3, Issue S1, Page 152-153, June 2019., 2019 Background: During carcinogenesis, tumor cells alter their immunogenicity in an attempt to escape surveillance of the immune system (SI). This surveillance process involves NK cells and T lymphocytes, and various immunological factors, in order to combat tumor progression.
R.S. Alves +8 more
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 153, June 2019., 2019 Background: The main feature of CML is the formation of the BCR‐ABL gene, the product of which has a pronounced tyrosine kinase activity, which is due to the suppressing effect of the protein regulators of proliferation and apoptosis. The result is an increase of the proliferation of tumor cells, the marker of which is the Ki‐67 protein.
T. Perekhrestenko +3 more
wiley +1 more source
PF403 NEGATIVE MR4.0 CHRONIC MYELOID LEUKEMIA AND ITS IMPLICATIONS FOR TREATMENT‐FREE REMISSION
HemaSphere, Volume 3, Issue S1, Page 153-154, June 2019., 2019 Background: In the last few years, several clinical discontinuation trials have demonstrated that 40–60% of chronic phase CML patients (CP‐CML) who have achieved a stable deep molecular response, can stop therapy without relapsing. However, there is no consensus as to whether or not the depth of the molecular response is a prognostic factor for ...
N. Cerveira +13 more
wiley +1 more source
HemaSphere, Volume 3, Issue S1, Page 395-396, June 2019., 2019 Background: Family planning is important in patients (pts) with chronic myeloid leukemia (CML) who can have a near normal lifespan in tyrosine kinase inhibitors (TKI) era. Management of CML on conceptions and pregnancies is not defined as cases are rare and data are scarce.
E. Chelysheva +27 more
wiley +1 more source